| Paroxysmal nocturnal hemoglobinuria
Soliris vs Bkemv
Side-by-side clinical, coverage, and cost comparison for paroxysmal nocturnal hemoglobinuria.Deep comparison between: Soliris vs Bkemv with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBkemv has a higher rate of injection site reactions vs Soliris based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Bkemv but not Soliris, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Soliris
Bkemv
At A Glance
IV infusion
Every 2 weeks
Complement C5 inhibitor
IV infusion
Every 2 weeks
Complement C5 inhibitor
Indications
- Paroxysmal nocturnal hemoglobinuria
- Atypical Hemolytic Uremic Syndrome
- Myasthenia Gravis, Generalized
- Neuromyelitis Optica
- Paroxysmal nocturnal hemoglobinuria
- Atypical Hemolytic Uremic Syndrome
- Myasthenia Gravis, Generalized
Dosing
Paroxysmal nocturnal hemoglobinuria 600 mg IV infusion weekly for 4 weeks, then 900 mg at week 5, then 900 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized, Neuromyelitis Optica (adults) 900 mg IV infusion weekly for 4 weeks, then 1200 mg at week 5, then 1200 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized (pediatric) Weight-based IV infusion dosing; induction and maintenance doses vary by body weight (5 kg to >=40 kg), administered every 2 to 3 weeks after induction.
Paroxysmal nocturnal hemoglobinuria 600 mg IV weekly for 4 weeks, then 900 mg at week 5, then 900 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized 900 mg IV weekly for 4 weeks, then 1,200 mg at week 5, then 1,200 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome (pediatric, <18 years) Weight-based IV dosing: induction 300-900 mg and maintenance 300-1,200 mg every 2-3 weeks depending on body weight (5 kg and over).
Contraindications
- Unresolved serious Neisseria meningitidis infection
- Unresolved serious Neisseria meningitidis infection
Adverse Reactions
Most common (>=5%) Headache, nasopharyngitis, back pain, nausea, fatigue, cough, herpes simplex infections, sinusitis, upper respiratory tract infection, diarrhea, vomiting, hypertension, musculoskeletal pain, abdominal pain, peripheral edema, pyrexia, arthralgia, influenza, contusion
Serious Meningococcal infections, other serious infections, disease exacerbation after SOLIRIS discontinuation, thrombosis, infusion-related reactions
Postmarketing Fatal or serious infections (Neisseria gonorrhoeae, Neisseria meningitidis, Neisseria sicca/subflava, Neisseria spp unspecified), cholestatic or mixed pattern liver injury in aHUS patients
Most common (>=5%) Headache, nasopharyngitis, back pain, nausea, fatigue, cough, herpes simplex infections, musculoskeletal pain, hypertension, diarrhea, vomiting, pyrexia, peripheral edema.
Serious Meningococcal infections, other serious infections, thrombosis, infusion-related reactions, disease manifestation exacerbation after discontinuation.
Postmarketing Fatal or serious infections (Neisseria gonorrhoeae, Neisseria meningitidis, Neisseria species), cholestatic or mixed pattern liver injury with elevated liver enzymes and bilirubin.
Pharmacology
Eculizumab is a monoclonal antibody that specifically binds complement protein C5 with high affinity, inhibiting its cleavage to C5a and C5b and preventing generation of the terminal complement complex C5b-9, thereby inhibiting terminal complement-mediated intravascular hemolysis in PNH, complement-mediated thrombotic microangiopathy in aHUS, and presumed reduction of terminal complement C5b-9 deposition at the neuromuscular junction in gMG and in NMOSD.
Complement C5 inhibitor; eculizumab-aeeb is a recombinant humanized monoclonal IgG2/4kappa antibody that specifically binds complement protein C5 with high affinity, inhibiting its cleavage to C5a and C5b and preventing generation of the terminal complement complex C5b-9, thereby inhibiting terminal complement-mediated intravascular hemolysis in PNH and complement-mediated thrombotic microangiopathy in aHUS.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Soliris
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
Bkemv
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Soliris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Bkemv
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Soliris
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Bkemv
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Soliris.
No savings programs available for Bkemv.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SolirisView full Soliris profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.